Piramal Pharma is an API manufacturer based in India. It holds 56 active US drug master files and 28 valid CEPs. Its filings concentrate with US FDA, ARCSA (EC) and TMDA (TZ). Its GMP standing is certified by EMA, MHRA (UK) and ANVISA (Brazil), among 5 authorities. Its most recent recorded inspection, by US FDA, closed on 17 February 2025 as VAI. Customs aggregates show $385.3M of exports covering 2,966 molecules to 100 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Mumbai, India | Not on file |
| Hyderabad, India | Not on file |
| Digwal Village, India | Not on file |
| PITHAMPUR, India | Not on file |
| ZAHEERABAD, India | Not on file |
| SANGAREDDY DISTRICT, India | Not on file |
5 further sites are on record.
| Molecule | Regulators | Docs |
|---|---|---|
| Verapamil | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Baclofen | EDQM, SFDA (Saudi Arabia), US FDA | 3 |
| Diltiazem | EDQM, US FDA | 3 |
| Amiodarone | EDQM, US FDA | 2 |
| Aprepitant | EDQM, US FDA | 2 |
| Bisoprolol | EDQM, US FDA | 2 |
| Brimonidine | EDQM, US FDA | 2 |
| Cinacalcet | SFDA (Saudi Arabia), US FDA | 2 |
| Desmopressin | EDQM, US FDA | 2 |
| Entacapone | EDQM, US FDA | 2 |
| Ketoconazole | EDQM, US FDA | 2 |
| Leuprolide | EDQM, US FDA | 2 |
| Mirabegron | EDQM, US FDA | 2 |
| Oxytocin | EDQM, US FDA | 2 |
| Terlipressin | EDQM, SFDA (Saudi Arabia) | 2 |
| Trazodone | EDQM, US FDA | 2 |
| Acyclovir | US FDA | 1 |
| Anagrelide | US FDA | 1 |
| Armodafinil | US FDA | 1 |
| Azilsartan Medoxomil | US FDA | 1 |
| Bexagliflozin | US FDA | 1 |
| Buserelin | EDQM | 1 |
| Calcitonin (Salmon) | EDQM | 1 |
| Cetrorelix | US FDA | 1 |
| Clobazam | US FDA | 1 |
| Dabigatran Etexilate | US FDA | 1 |
| Dabigatran Etexilate Mesilate | EDQM | 1 |
| Dapagliflozin | US FDA | 1 |
| Dapagliflozin Propanediol | SFDA (Saudi Arabia) | 1 |
| Deferasirox | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | 9 | 2 |
| ARCSA (EC) | 6 | None |
| TMDA (TZ) | 3 | 1 |
| DPM (TN) | 3 | None |
| RAMA (GE) | 3 | None |
| CDSCO (India) | 2 | None |
| EMA | None | 5 |
| MHRA (UK) | None | 4 |
| ANVISA (Brazil) | None | 2 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | $1.0B | $395.6M | 52 |
| 2025 | $1.1B | $385.3M | 100 |
| 2024 | $976.5M | $373.2M | 91 |
| 2023 | Not reported | $215.7M | 100 |
Export figures are customs aggregates. We do not publish the identity of any buyer. Revenue shown in US dollars, converted from the reported currency.
Choose your molecules and target markets. Piramal Pharma comes back tiered against every other supplier able to file there.
Start for free